The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index; 4 of the 8 sources its claims cite were checked for support.
A prudent path forward for genomic engineering and germline gene modification
Open accessAbstract
A framework for open discourse on the use of CRISPR-Cas9 technology to manipulate the human genome is urgently needed , Genome engineering technology offers unparalleled potential for modifying human and nonhuman genomes. In humans, it holds the promise of curing genetic disease, while in other organisms it provides methods to reshape the biosphere for the benefit of the environment and human societies. However, with such enormous opportunities come unknown risks to human health and well-being. In January, a group of interested stakeholders met in Napa, California ( 1 ), to discuss the scientific, medical, legal, and ethical implications of these new prospects for genome biology. The goal was to initiate an informed discussion of the uses of genome engineering technology, and to identify those areas where action is essential to prepare for future developments. The meeting identified immediate steps to take toward ensuring that the application of genome engineering technology is performed safely and ethically.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
A 2015 Science policy forum from the Napa meeting argues that CRISPR-Cas9 genome engineering offers major promise but also unknown risks, especially for human germline modification. It recommends broad open discussion and, in the near term, strongly discouraging clinical human germline genome modification while research and governance proceed.
Key findings
- The Napa meeting concluded there is an urgent need for open discussion of the merits and risks of human genome modification by a broad cohort including scientists, clinicians, social scientists, the general public, and relevant public entities and interest groups.
- Near-term recommendations include strongly discouraging germline genome modification for clinical application in humans, even in lax jurisdictions; creating expert forums for education; encouraging transparent research on efficacy and specificity in human and nonhuman model systems; and convening a globally representative group to consider policies.
- The paper notes that human germline engineering methods have already been demonstrated in mice and monkeys, and it distinguishes mitochondrial transfer—which does not use CRISPR-Cas9 and was approved by the Human Fertilisation and Embryology Authority and by Parliament in the United Kingdom—from nuclear germline editing.
- No quantitative data or effect sizes are reported; the text is a consensus policy commentary.
Methods
- Design: policy forum/commentary reporting on a January 2015 Napa, California meeting of CRISPR-Cas9 developers and users and experts in genetics, law, and bioethics; all participants were from the United States.
- Data or sample: no empirical dataset; discussion focused on human germline engineering and did not address mitochondrial transfer.
- Main analysis: consensus discussion and recommendations for governance, risk assessment, public engagement, and research priorities.
Limitations
- Stated: the Napa discussion did not address mitochondrial transfer; the group was all from the United States, and the paper calls for globally representative participation.
- Stated: limits to knowledge of human genetics, gene-environment interactions, and disease pathways create uncertainty about unintended consequences of heritable germline modifications.
- Evident from the text: the recommendations are not based on systematic data or quantitative risk assessment and are advisory rather than binding.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 of 8 cited sources checked · 3 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“focused on the issue of human germline engineering, as the methods have already been demonstrated in mice (6) and monkeys (7).”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
What the sources say
- Supportedcites [6] Wang H Cell 2013 153 910 Medline 23643243 PMC3969854 source
The Introduction states that the authors use CRISPR/Cas to edit multiple genes in stem cells and mice, and the Discussion reports generating mice with multiple genetic alterations. This source supports the mice portion of the citing sentence; the monkeys portion is assigned to a separate citation. (LLM, conf=0.93)
- Supportedcites [7] Niu Y Cell 2014 156 836 Medline 24486104 source
The citation to this paper supports the monkey part of the sentence. The Summary reports CRISPR/Cas9 gene targeting in one-cell-stage cynomolgus monkey embryos and the generation of gene-modified monkeys; the mice citation is separate. (LLM, conf=0.93)
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The technique also allows DNA sequence changes in pluripotent embryonic stem cells (4) that can then be cultured to produce specific tissues, such as cardiomyocytes or neurons (5).”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
What the sources say
- Partly supportedcites [4] Mali P Science 2013 339 823 Medline 23287722 PMC3712628 sourceExperimental — accuracy not yet measured
The paper’s genome-targeting results report CRISPR-Cas9 editing in human induced pluripotent stem (iPS) cells, supporting the claim that the technique can change DNA in pluripotent cells. It does not report editing embryonic stem cells; the citing sentence attaches this source to that part, while assigning the tissue-differentiation claim to citation (5). (LLM, conf=0.88)
- Supportedcites [5] Zhu Z González F Huangfu D Methods Enzymol 2014 546 215 Medline 25398343 PMC4418970 source
Citation (4) is attached to the claim that CRISPR-Cas9 allows DNA sequence changes in pluripotent embryonic stem cells, not to the later examples of cardiomyocytes or neurons. The Introduction identifies human embryonic stem cells as human pluripotent stem cells and describes CRISPR/Cas genome editing in those cells; Section 2 reports highly efficient editing at target loci. (LLM, conf=0.93)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
In the paper
“Although characterized by some as another form of “germline” engineering, mitochondrial transfer raises different issues and has already been approved by the Human Fertilisation and Embryology Authority and by Parliament in the United Kingdom (10) and is being considered by the Institute of Medicine and the Food and Drug Administration in the United States (11).”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
What the sources say
- Not matchedcites [11] U.S. Food and Drug Administration, Cellular, Tissue, and Gene Therapies Advisory Committee Meeting: Announcement www.fda.gov/AdvisoryCommittees/Calendar/ucm380042.htm; www.iom.edu/activities/research/mitoethics.aspx.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Humans are no exception—changes to the human germ line could be made using this simple and widely available technology.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: CRISPR-Cas9 and other genome engineering methods can be used to change DNA in the nuclei of reproductive cells (germ line).
In the paper
“For example, the CRISPR-Cas9 system enables introduction of DNA sequence changes that correct genetic defects in whole animals, such as replacing a mutated gene underlying liver-based metabolic disease in a mouse model (3).”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
What the sources say
- Not checked yetcites [3] Yin H Nat. Biotechnol 2014 32 551 Medline 24681508 PMC4157757 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Even this seemingly straightforward scenario raises serious concerns, including the potential for unintended consequences of heritable germline modifications,”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: There are limits to current knowledge of human genetics, gene-environment interactions, and disease pathways.
- Probably not a substantial claim. 2
- It may state two separate claims as one. 3
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Such studies are laying the groundwork for refined approaches that could eventually treat human disease.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
In the paper
“Although characterized by some as another form of “germline” engineering, mitochondrial transfer raises different issues and has already been approved by the Human Fertilisation and Embryology Authority and by Parliament in the United Kingdom (10) and is being considered by the Institute of Medicine and the Food and Drug Administration in the United States (11).”
§ A prudent path forward for genomic engineering and germline gene modification > MOVING FORWARD
What the sources say
- Not checked yetcites [10] The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015 www.legislation.gov.uk/uksi/2015/572/contents/made (effective 29 October 2015).
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“However, this limitation has been upended by the rapid development and widespread adoption of a simple, inexpensive, and remarkably effective genome engineering method known as clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 (2).”
§ A prudent path forward for genomic engineering and germline gene modification > Abstract
What the sources say
- Not matchedcites [2] Doudna JA Charpentier E Science 2014 346 1258096 Medline 25430774
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The simplicity of the CRISPR-Cas9 system allows any researcher with knowledge of molecular biology to modify genomes, making feasible experiments that were previously difficult or impossible to conduct.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, it is now possible to carry out genome modification in fertilized animal eggs or embryos, thereby altering the genetic makeup of every differentiated cell in an organism and so ensuring that the changes will be passed on to the organism’s progeny.”
§ A prudent path forward for genomic engineering and germline gene modification > CURRENT APPLICATIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
- Rests on an assumption: CRISPR-Cas9 and other genome engineering methods can be used to change DNA in the nuclei of reproductive cells (germ line).
The paper relies on this without support.
There are limits to current knowledge of human genetics, gene-environment interactions, and disease pathways.
“because there are limits to our knowledge of human genetics, gene-environment interactions, and the pathways of disease (including the interplay between one disease and other conditions or diseases in the same patient).”
The paper relies on this without support.
In the United States, human research involving heritable germline modifications currently would require an Investigational New Drug exemption from the FDA.
“In the United States, such human research currently would require an Investigational New Drug exemption from the Food and Drug Administration”
The paper relies on this without support.
In countries with a highly developed bioscience capacity, germline genome modification in humans is currently illegal or tightly regulated.
“(In countries with a highly developed bioscience capacity, germline genome modification in humans is currently illegal or tightly regulated.)”
The paper relies on this without support.
Mitochondrial transfer does not use CRISPR-Cas9.
“The Napa discussion did not address mitochondrial transfer (8, 9), a technique that does not use CRISPR-Cas9.”
The paper relies on this without support.
Public trust in science ultimately begins with and requires ongoing transparency and open discussion.
“At the dawn of the recombinant DNA era, the most important lesson learned was that public trust in science ultimately begins with and requires ongoing transparency and open discussion.”
The paper relies on this without support.
CRISPR-Cas9 and other genome engineering methods can be used to change DNA in the nuclei of reproductive cells (germ line).
“In addition to facilitating changes in differentiated somatic cells of animals and plants, CRISPR-Cas9 technology as well as other genome engineering methods can be used to change the DNA in the nuclei of reproductive cells that transmit information from one generation to the next (an organism’s “germ line”).”
The paper relies on this without support.
Off-target alterations and on-target events with unintended consequences are possible with CRISPR-Cas9.
“Considerations include the possibility of off-target alterations, as well as on-target events that have unintended consequences.”
The authors state this as an assumption.
The safety and efficacy of genome engineering technology can be ensured.
“Assuming the safety and efficacy of the technology can be ensured, a key point of discussion is whether the treatment or cure of severe diseases in humans would be a responsible use of genome engineering, and if so, under what circumstances.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subsequent report of the results of the conference was published in March 2015 in the journal Science [46], which essentially carried recommendations to strongly discourage work on introducing heritable changes in human embryonic cells, at least for the duration of active discussions of the social, environmental and ethical consequences of such manipulations.”
From CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing (2022) · cites this paper as [46]
Citations
Cites
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Self-citationThe new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Self-citationWang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Niu, Y., Shen, B., Cui, Y., Chen, Y., Wang, J., Wang, L., Kang, Y., Zhao, X., Si, W., Li, W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.027 · Cited by 1,033
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Towards germline gene therapy of inherited mitochondrial diseases
Tachibana, M., Amato, P., Sparman, M. L., Woodward, J., Melguizo‐Sanchis, D., Ma, H., Gutiérrez, N. M., Tippner-Hedges, R., Kang, E., Lee, H.-S., et al. (2012) · Nature · doi:10.1038/nature11647 · Cited by 429
The iCRISPR Platform for Rapid Genome Editing in Human Pluripotent Stem Cells
Zhu, Z., González, F., & Huangfu, D. (2014) · Methods in Enzymology · doi:10.1016/b978-0-12-801185-0.00011-8 · Cited by 66
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 733
ALTERING THE HUMAN GENOME: MAPPING THE GENOME EDITING REGULATORY SYSTEM IN SOUTH AFRICA
Townsend, B., & Shozi, B. (2021) · Potchefstroom Electronic Law Journal/Potchefstroomse Elektroniese Regsblad · doi:10.17159/1727-3781/2021/v24i0a9179 · Cited by 9
Romano, C. P. R., & Boggio, A. (2024) · Oxford University Press eBooks · doi:10.1093/law/9780197768990.001.0001 · Cited by 9
Pila, J. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0504-5 · Cited by 9
Alón, I., Urbanos-Garrido, R. M., & Guimón, J. (2021) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-020-02017-9 · Cited by 9
‘Eugenics is Back’? Historic References in Current Discussions of Germline Gene Editing
Ranisch, R. (2019) · NanoEthics · doi:10.1007/s11569-019-00351-6 · Cited by 9
Applications and limitations in translating genomics to clinical practice
Ness, B. G. V. (2015) · Translational research · doi:10.1016/j.trsl.2015.04.012 · Cited by 9
Treading the Line Between Sensational and Groundbreaking Science
Scott, C. T. (2015) · The American Journal of Bioethics · doi:10.1080/15265161.2015.1119012 · Cited by 9
Pache, M. M., Pangavhane, R. R., Nikam, S. V., Rode, R. B., & Darekar, A. B. (2025) · Research Journal of Science and Technology · doi:10.52711/2231-5713.2025.00045 · Cited by 8
Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects
Singh, K., Bhushan, B., Kumar, S., Singh, S., Macadangdang, R. R., Pandey, E., Varma, A. K., & Kumar, S. (2024) · Current Gene Therapy · doi:10.2174/0115665232279528240115075352 · Cited by 9
Técnica de edición de genes CRISPR / CAS9. Retos jurídicos para su regulación y uso en Colombia
Lamprea, N., & Lizarazo-Cortés, Ó. (2016) · Revista La Propiedad Inmaterial · doi:10.18601/16571959.n21.04 · Cited by 8
Prioritizing Women's Health in Germline Editing Research
(2019) · AMA Journal of Ethics · doi:10.1001/amajethics.2019.1071 · Cited by 6
Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy
Arnesen, V. S., Navarro, A. G., & Chekenya, M. (2021) · Cancers · doi:10.3390/cancers13194986 · Cited by 8
The Geographies and Politics of Gene Editing: Framing Debates Across Seven Countries
Meyer, M., & Vergnaud, F. (2021) · Frontiers in Political Science · doi:10.3389/fpos.2021.731496 · Cited by 8
Madhu, A., Cherian, I., & Gautam, A. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85156-5.00018-3 · Cited by 8
Using Genome Engineering to Understand Huntington’s Disease
Bailus, B. J., Zhang, N., & Ellerby, L. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2_9 · Cited by 8
Ouagrham-Gormley, S. B., & Fye-Marnien, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-03053-7_12 · Cited by 8
Errigo, M. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-38840-9_10 · Cited by 8
Editing the Genome of Human Being
de Araújo, M. (2017) · Journal of Ethics and Emerging Technologies · doi:10.55613/jeet.v27i1.65 · Cited by 8
Geo-ecology in the Anthropocene
Nadal‐Romero, E., & Cammeraat, E. (2018) · Cuadernos de Investigación Geográfica · doi:10.18172/cig.3876 · Cited by 8
Shaping the CRISPR Gene-Editing Debate: Questions About Enhancement and Germline Modification
Johnston, J. (2020) · Perspectives in biology and medicine · doi:10.1353/pbm.2020.0011 · Cited by 8
Metal-based biomaterials for cancer gene therapy
Li, S., Zhang, C., Xu, X., Wang, X., Ren, H., Sun, B., & Zhang, Y. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216720 · Cited by 7
The Future of CRISPR Applications in the Lab, the Clinic and Society
Hough, S. H., & Ajetunmobi, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_9 · Cited by 7
Parenting in the Age of Preimplantation Gene Editing
Klipstein, S. (2017) · The Hastings Center Report · doi:10.1002/hast.792 · Cited by 7
Enter CRISPR: Jennifer Doudna's Autobiographical Assessment of the Science and Ethics of CRISPR/Cas9
Zwart, H. A. E. (2018) · Ethics in Biology Engineering and Medicine An International Journal · doi:10.1615/ethicsbiologyengmed.2019030275 · Cited by 7
Therapeutic gene editing is here, can regulations keep up?
Kannan, S., & Najjar, D. (2020) · MIT Science Policy Review · doi:10.38105/spr.czm9c2w8ig · Cited by 7
Christian, A. (2022) · Frontiers in Research Metrics and Analytics · doi:10.3389/frma.2022.775336 · Cited by 7
Advances in Genetic Editing of the Human Embryo
Astărăstoae, V., Ioan, B. G., Rogozea, L. M., & Hanganu, B. (2023) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001604 · Cited by 7
Legislation governing pluripotent stem cells in South Africa
Pepper, M. S., Gouveia, C., & Slabbert, M. N. (2015) · South African Journal of Bioethics and Law · doi:10.7196/sajbl.8402 · Cited by 7
Kirchner, M., & Schneider, S. (2015) · Angewandte Chemie · doi:10.1002/ange.201504741 · Cited by 7
A Perspective on the State of Genome Editing
Carroll, D. (2016) · Molecular Therapy · doi:10.1038/mt.2016.28 · Cited by 7
Self-citationPenchaszadeh, V. B. (2016) · Escritos · doi:10.18566/escr.v24n53.a09 · Cited by 7
Transplantation and Culture of Spermatogonial Stem Cells
Kubota, H., & Brinster, R. L. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7505-1_11 · Cited by 7
From Asilomar to Genome Editing: Research Ethics and Models of Decision
Rufo, F., & Ficorilli, A. (2019) · NanoEthics · doi:10.1007/s11569-019-00356-1 · Cited by 7
Targeted insertion of large genetic payloads using cas directed LINE-1 reverse transcriptase
Manoj, F., Tai, L. W., Wang, K. S. M., & Kuhlman, T. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-03130-0 · Cited by 7
How should China set ethical guardrails for medical research?
Xu, J., Liu, Z., Shi, J., & Wang, Y. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2023-109621 · Cited by 7
Minssen, T., & Nordberg, A. (2015) · Biotechnology Law Report · doi:10.1089/blr.2015.29004 · Cited by 7
Science Policy and Concomitant Research in Synthetic Biology—Some Critical Thoughts
Hagen, K. (2016) · NanoEthics · doi:10.1007/s11569-016-0267-0 · Cited by 7
Editing the Genome: Prospects, Progress, Implications, and Cautions
King, N. M. P., Lord, P. C. W., & Lemley, D. E. (2017) · Current Genetic Medicine Reports · doi:10.1007/s40142-017-0109-6 · Cited by 7
Drawing the Line: Disability, Genetic Intervention and Bioethics
Conti, A. (2017) · Laws · doi:10.3390/laws6030009 · Cited by 7
Németh, E., Asaka, M. N., Kato, K., Fábián, Z., Oostenbrink, C., Christensen, H. E. M., Nagata, K., & Gyurcsik, B. (2017) · ChemBioChem · doi:10.1002/cbic.201700420 · Cited by 7
Ethics of embryo editing paper divides scientists
Reardon, S. (2015) · Nature · doi:10.1038/nature.2015.17410 · Cited by 7
Ethical Considerations in the Manufacture, Sale, and Distribution of Genome Editing Technologies
Sugarman, J., Shivakumar, S., Rook, M. S., Loring, J. F., Rehmann‐Sutter, C., Taupitz, J., Reinhard-Rupp, J., & Hildemann, S. K. (2018) · The American Journal of Bioethics · doi:10.1080/15265161.2018.1489653 · Cited by 7
Gene editing for advanced therapies
Garden, H., & Winickoff, D. E. (2018) · OECD science, technology and industry working papers · doi:10.1787/8d39d84e-en · Cited by 7
Botelho, A. (2019) · Science as Culture · doi:10.1080/09505431.2019.1623190 · Cited by 6
Non-mass spectrometric targeted single-cell metabolomics
Cheng, H., Tang, Y., Li, Z., Guo, Z., Heath, J. R., Xue, M., & Wei, W. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117300 · Cited by 6
Pergament, E. (2016) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000255 · Cited by 6
Addison, C., & Taylor‐Alexander, S. (2015) · Science · doi:10.1126/science.349.6251.935-a · Cited by 6
Benston, S. (2022) · Journal of Bioethical Inquiry · doi:10.1007/s11673-022-10186-8 · Cited by 6
The genome editing revolution: A CRISPR-Cas TALE off-target story
Stella, S., & Montoya, G. (2015) · Inside the Cell · doi:10.1002/icl3.1038 · Cited by 6
Chinese biotech versus international ethics? Accounting for the China–America CRISPR ethical divide
Jiang, L., & Stevens, H. (2015) · BioSocieties · doi:10.1057/biosoc.2015.34 · Cited by 6
Technology assessment and the social and human impact of innovation
Phillips, F. Y., & Oh, D.-S. (2016) · Bulletin of the Atomic Scientists · doi:10.1080/00963402.2016.1240484 · Cited by 6
Precision medicine, agriculture, and genome editing: science and ethics
Moscoso, C. G., Potz, K. R., Tan, S., Jacobson, P. A., Berger, K. M., & Steer, C. J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14266 · Cited by 6
Schick, A. (2019) · NanoEthics · doi:10.1007/s11569-019-00350-7 · Cited by 6
CRISPR's Twisted Tales: Clarifying Misconceptions about Heritable Genome Editing
Darnovsky, M., & Hasson, K. (2020) · Perspectives in biology and medicine · doi:10.1353/pbm.2020.0012 · Cited by 6
Contemporary Debates in Bioethics: European Perspectives
Mihailov, E., Wangmo, T., Federiuc, V. V., & Elger, B. S. (2018) · doi:10.2478/9783110571219 · Cited by 6
Medicine, patients and the law (sixth edition)
Brazier, M., & Cave, E. (2020) · Manchester University Press eBooks · doi:10.7765/9781526153425 · Cited by 6
GEMMs addressing Pax5 loss-of-function in childhood pB-ALL
Auer, F., Ingenhag, D., Bhatia, S., Enczmann, J., Cobaleda, C., Sánchez-Garcı́a, I., Borkhardt, A., & Hauer, J. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.11.009 · Cited by 6
Applications of CRISPR-Cas in its natural habitat
Hynes, A. P., Lemay, M.-L., & Moineau, S. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.05.021 · Cited by 5
Role of genetically modified organisms in food, crop production, their regulations, and controversy
Tahir, M. S., Gondal, A. H., Tariq, H., Shah, A. I., Ali, M. N., & Bajwa, Z. A. (2024) · CABI Reviews · doi:10.1079/cabireviews.2024.0012 · Cited by 5
Aftermath of the Human Genome Project: an era of struggle and discovery
HAMDOUN, Z., & Ehsan, H. (2017) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1609-77 · Cited by 5
Burly1 is a mouse QTL for lean body mass that maps to a 0.8-Mb region of chromosome 2
Lin, C., Fesi, B. D., Marquis, M., Bosak, N. P., Lysenko, A., Koshnevisan, M. A., Duke, F. F., Theodorides, M. L., Nelson, T. M., McDaniel, A. H., et al. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9746-7 · Cited by 5
Why the genomic LOCATION of individual SNPs is FUNCTIONAL?
Perez, J. C. (2017) · SDRP Journal of Cellular and Molecular Physiology · doi:10.25177/jcmp.2.1.4 · Cited by 5
Paving the way for a softer regulation of CRISPR in Norway: public engagement as window dressing
Svingen, M. (2022) · Journal of Responsible Innovation · doi:10.1080/23299460.2022.2146863 · Cited by 5
Discussions on Human Enhancement Meet Science: A Quantitative Analysis
Żuradzki, T., Bystranowski, P., & Dranseika, V. (2025) · Science and Engineering Ethics · doi:10.1007/s11948-025-00531-6 · Cited by 5
Precision Medicine and Challenges in Research and Clinical Implementation
Haga, S. B. (2017) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-803506-1.00021-8 · Cited by 5
Le rôle des traces dans le système immunitaire : des anticorps au corps
Thomas‐Vaslin, V. (2017) · CNRS Éditions eBooks · doi:10.4000/books.editionscnrs.29917 · Cited by 5
Chapter 12 Gene Editing in Human Embryos. A Comment on the Ethical Issues Involved
Beriaín, Í. D. M., & del Cano, A. M. M. (2018) · Philosophy and medicine · doi:10.1007/978-3-319-60684-2_12 · Cited by 5
Tan, Z. Y., Huang, T., & Ngeow, J. Y. Y. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0039 · Cited by 5
From pathogenesis to novel therapies in primary hyperoxaluria
Rumsby, G., & Hulton, S. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1571905 · Cited by 5
CRISPR-Cas9, cellules germinales et embryon humain
Jouannet, P. (2017) · Biologie Aujourd hui · doi:10.1051/jbio/2017032 · Cited by 5
Advancing Adverse Outcome Pathways for Risk Assessment
García‐Reyero, N., & Murphy, C. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-66084-4_1 · Cited by 5
Chapter 11 Germline Gene Therapy in the Era of Precise Genome Editing: How Far Should We Go?
Sýkora, P. (2018) · Philosophy and medicine · doi:10.1007/978-3-319-60684-2_11 · Cited by 5
Agent-Based Models of Dual-Use Research Restrictions
Wagner, E. O., & Herington, J. (2019) · The British Journal for the Philosophy of Science · doi:10.1093/bjps/axz017 · Cited by 5
Considerations on genetic engineering: regarding the birth of twins subjected to gene edition
Santillán‐Doherty, P., Grether-González, P., Arellano, M. D. J. M., Chan, S., Tapia-Ibargüengoitia, R., Sesma, I. B., de la Fuente, R. C., Linares-Salgado, J., Cárdenas, H. A. M., Muñoz-Fernández, L., et al. (2019) · Gaceta Médica de México · doi:10.24875/gmm.19005182 · Cited by 5
66. The ethical dilemma with governing CRISP/Cas genome editing
Pirscher, F., & Theesfeld, I. (2018) · Congress of the European Society for Agricultural and Food Ethics (EurSafe) · doi:10.3920/978-90-8686-869-8_66 · Cited by 5
Exosomal miRNA in early-stage hepatocellular carcinoma
Wu, Z., Zhu, Y.-X., Jin, Y., & Zhan, Y.-C. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i3.528 · Cited by 5
Un análisis ético de las nuevas tecnologías de edición genética: el CRISPR-Cas9 a debate
Beriaín, Í. D. M., & Armaza, E. A. (2017) · Anales de la Cátedra Francisco Suárez · doi:10.30827/acfs.v52i0.6555 · Cited by 5
Who's Afraid of the Big Bad (Germline Editing) Wolf?
Charo, R. A. (2020) · Perspectives in biology and medicine · doi:10.1353/pbm.2020.0007 · Cited by 5
Self-citationCRISPR germline editing reverberates through biotech industry
Sheridan, C. (2015) · Nature Biotechnology · doi:10.1038/nbt0515-431 · Cited by 5
Germline Genome Editing and the Functions of Consent
Ranisch, R. (2017) · The American Journal of Bioethics · doi:10.1080/15265161.2017.1388875 · Cited by 4
Next-generation genome editing
(2015) · Nature Biotechnology · doi:10.1038/nbt.3234 · Cited by 5
Martani, A., van der Weij, F., van Baalen, S., & van Beers, B. C. (2025) · New Genetics and Society · doi:10.1080/14636778.2025.2598071 · Cited by 4
Edição de genes CRISPR-Cas9 e suas aplicações terapêuticas: Uma revisão de literatura
Mendes, L. M. C., Lino, L. A., Bordignon, T. M., de Castro, M. M., Bartholomeu, L. M. D. D. O., de Almeida, Z. S., Carneiro, I. M. V., da Silva, I. M., Martins, I. D. R., Honorato, M. P. P., et al. (2024) · Research Society and Development · doi:10.33448/rsd-v13i8.46681 · Cited by 4
Grüne Gentechnik und Genome Editing
Albrecht, S., Diekämper, J., Marx-Stölting, L., & Sauter, A. (2017) · TATuP - Zeitschrift für Technikfolgenabschätzung in Theorie und Praxis · doi:10.14512/tatup.26.3.64 · Cited by 4
Learning from Icarus: The Impact of CRISPR on Gene Editing Ethics
Parent, B. (2023) · Collaborative bioethics · doi:10.1007/978-3-031-29451-8_2 · Cited by 4
How Advanced are Nanocarriers for Effective Subretinal Injection?
Guan, J.-X., Wang, Y.-L., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479327 · Cited by 4
Summitting CRISPR for Human Heritable Genome Editing
Baylis, F. E. (2025) · The CRISPR Journal · doi:10.1089/crispr.2025.0051 · Cited by 4
The Application of CRISPR/Cas9 Technologies and Therapies in Stem Cells
Scholefield, J., & Weinberg, M. S. (2016) · Current Stem Cell Reports · doi:10.1007/s40778-016-0043-7 · Cited by 4
Walter, J., Taupitz, J., Schickl, H., Reich, J., Müller‐Röber, B., Marx-Stölting, L., Körte, M., Könninger, S., Köchy, K., Hucho, F., et al. (2018) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783845293790 · Cited by 4
Between Moral Hazard and Legal Uncertainty
Braun, M., Schickl, H., & Dabrock, P. (2018) · Technikzukünfte, Wissenschaft und Gesellschaft · doi:10.1007/978-3-658-22660-2_1 · Cited by 4
Convergence Education of Medicine and Theology in a Secular Age
Kwon, S.-Y., Cho, N. H., & Son, M. (2018) · Education Sciences · doi:10.3390/educsci8040201 · Cited by 4
Beriaín, Í. D. M. (2019) · Revista de Bioética y Derecho · doi:10.1344/rbd2019.0.29200 · Cited by 4
Dangerous Science Science: Policy and Risk Analysis for Scientists and Engineers
Rozell, D. J. (2020) · Ubiquity Press eBooks · doi:10.5334/bci · Cited by 4
CRISPR-CAS UYGULAMALARI, POTANSİYEL RİSKLER VE YASAL DÜZENLEMELER
TOSUN, Ö. K., & Kesmen, Z. (2022) · Helal ve Etik Araştırmalar Dergisi · doi:10.51973/head.1209563 · Cited by 4
Consensus too soon: judges’ and lawyers’ views on genetic information use
Selita, F., Chapman, R., Kovas, Y. V., Smereczynska, V., Likhanov, M. V., & Toivainen, T. (2023) · New Genetics and Society · doi:10.1080/14636778.2023.2197583 · Cited by 4
Trends Innovations Challenges in Employing Interdisciplinary Approaches to Biomedical Sciences
Ganeshkumar, M., Ayyadhury, S., & Murugan, E. (2024) · Springer eBooks · doi:10.1007/978-981-97-1777-4_20 · Cited by 4
Genome Editing and Dialogic Responsibility: “What's in a Name?”
Blasimme, A., Anegón, I., Concordet, J., Vos, J. D., Dubart‐Kupperschmitt, A., Fellous, M., Fouchet, P., Frydman, N., Giovannangeli, C., Jouannet, P., et al. (2015) · The American Journal of Bioethics · doi:10.1080/15265161.2015.1103811 · Cited by 4
A comparative study on the governance approaches for biotechnological risks
Wang, Y. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1647204 · Cited by 3
Una alarma nada excepcional: CRISPR/Cas9 y la edición de la línea germinal en seres humanos
Pallitto, N., & Folguera, G. (2020) · Bioethics Update · doi:10.1016/j.bioet.2019.12.002 · Cited by 3
Gene Editing and Germ-line Intervention: The Need for Novel Responses to Novel Technologies
Addison, C., & Taylor‐Alexander, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.185 · Cited by 3
Metadata
- Authors
- Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., Corn, J. E., Daley, G. Q., Doudna, J. A., Fenner, M., Greely, H. T., Jinek, M., Martin, G. S., Penhoet, E., Puck, J., Sternberg, S. H., Weissman, J. S., & Yamamoto, K. R.
- Affiliations
- California Institute of Technology (US)
- Stanford Medicine (US)
- Innovative Genomics Institute (US)
- University of Utah (US)
- University of Wisconsin–Madison (US)
- Harvard University (US)
- Boston Children's Hospital (US)
- Howard Hughes Medical Institute (US)
- Stanford University (US)
- Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
- University of California, Berkeley (US)
- Alta Partners, One Embarcadero Center, 37th Floor, San Francisco, CA 94111, USA.
- University of California, San Francisco (US)
- Corresponding author
- Doudna, Jennifer A.
- Venue
- Science
- Published
- 2015-04-03
- Volume
- 348
- Issue
- 6230
- Pages
- 36-38
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4394183
- OpenAlex
- W1987739153
- Cited by
- 733
- References
- 7
- Citations by year
- 2026: 37 · 2025: 28 · 2024: 48 · 2023: 34 · 2022: 52 · 2021: 46 · 2020: 77 · 2019: 74 · 2018: 75 · 2017: 96 · 2016: 80 · 2015: 84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Caribou Biosciences, Inc.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics and bioethics in healthcare
- Keywords
- CRISPR/Cas9, germline editing, public discourse, genome editing regulation
- MeSH terms
- Biotechnology, Genetic Engineering, Germ Cells, Humans, Risk Management, Genome, Human, Genetic Predisposition to Disease, Gene Transfer, Horizontal, Genomics, Targeted Gene Repair, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
